US › Healthcare

Virax Biolabs Group Limited Ordinary Shares (VRAX)

US · Healthcare · Biotechnology

$2.98+1.36%

Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue

$10,815

Revenue YoY

-86.5%

Net profit

$-2.7M

Profit YoY

+29.8%

EPS

$-0.49

EPS estimate

$0.00

Net margin

-24,826.4%

Key statistics

Market cap

$2.3M

Forward P/E

0.0

P/B

0.28

Book value

$13.08

EPS (TTM)

$-12.64

52-week high

$21.75

52-week low

$2.50

50-day MA

$4.22

200-day MA

$6.92

Beta

1.34

Analyst view

Analysts rate Virax Biolabs Group Limited Ordinary Shares a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $25.00.

Shareholding

Insiders

2.62%

Institutions

4.61%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	11.84%
Jump Financial LLC	0.55%
Advisor Group Holdings, Inc.	0.00%
NATIONAL BANK OF CANADA /FI/	0.00%
XTX Topco Ltd	0.00%
Northwestern Mutual Wealth Management Co	0.00%
UBS Group AG	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Virax Biolabs Group Limited Ordinary Shares — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.